Orforglipron

Overview

Orforglipron (brand name Foundayo) is Eli Lilly's oral non-peptide small-molecule GLP-1 receptor agonist. Unlike oral semaglutide (Rybelsus), it does not require the SNAC absorption enhancer or fasting/water restrictions — it can be taken any time of day. Not a peptide.

Mechanism of Action

Biased small-molecule GLP-1 receptor agonist with oral bioavailability. Activates GLP-1R to suppress appetite, slow gastric emptying, and enhance glucose-dependent insulin secretion. The non-peptide scaffold resists proteolytic degradation in the GI tract, removing the need for absorption enhancers.

Research Summary

ATTAIN-1 Phase 3 (n=3,127, non-diabetic obesity): mean body-weight change -11.2% with 36 mg at week 72 vs -2.1% placebo; ~59.6% of the 36 mg arm achieved ≥10% loss (Wharton et al., NEJM 2025). ATTAIN-2 (T2D obesity) and the ACHIEVE program (T2D glycemic control) were also positive. FDA approved April 1, 2026 as Foundayo under the Commissioner's National Priority Voucher program for adults with obesity or overweight with ≥1 weight-related comorbidity — the first oral small-molecule GLP-1 RA approved in the US.

Dosing Information

Reported Side Effects

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Dyspepsia

Research References

• Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1) — Wharton et al., NEJM (2025)
• FDA Approves First New Molecular Entity Under National Priority Voucher Program (Foundayo / orforglipron) (2026)
• FDA approves Lilly's Foundayo (orforglipron) — Eli Lilly investor release (2026)